ArticleMedical oncology (Northwood, London, England)2012

Imatinib has the potential to exert its antileukemia effects by down-regulating hERG1 K+ channels in chronic myelogenous leukemia.

Fang Zheng et al.PubMed ↗Publisher ↗

No numbers read from the abstract.